Presentation is loading. Please wait.

Presentation is loading. Please wait.

Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016  Murray Epstein, MD, Daniel A. Duprez,

Similar presentations


Presentation on theme: "Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016  Murray Epstein, MD, Daniel A. Duprez,"— Presentation transcript:

1 Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016  Murray Epstein, MD, Daniel A. Duprez, MD, PhD  The American Journal of Medicine  Volume 129, Issue 7, Pages (July 2016) DOI: /j.amjmed Copyright © 2016 Elsevier Inc. Terms and Conditions

2 Figure Mechanism-based algorithm treatment for resistant hypertension. ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; MRA = mineralocorticoid receptor antagonist. The American Journal of Medicine  , DOI: ( /j.amjmed ) Copyright © 2016 Elsevier Inc. Terms and Conditions


Download ppt "Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016  Murray Epstein, MD, Daniel A. Duprez,"

Similar presentations


Ads by Google